Physician profile
Glen D Garson
NPI 1699746214
$6,942.53
in general payments reported to CMS, 2019-2025
32 companies · $807 in 2025
The $807 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,994 · 2020: $668 · 2021: $858 · 2022: $706 · 2023: $643 · 2024: $1,266 · 2025: $807.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,716.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,715.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,562.89 | 2019-2025 | Comet, Watchman Flx, Polaris Ultra |
| Novartis Pharmaceuticals Corporation | $1,062.23 | 2019-2025 | |
| Amgen INC. | $630.21 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $501.82 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $370.23 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $300.05 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $287.69 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $285.03 | 2019-2025 | Farxiga |
| Novo Nordisk INC | $270.13 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Heartflow, INC. | $208.73 | 2023-2025 | Ffrct |
| Alnylam Pharmaceuticals INC. | $177.11 | 2021-2025 | Onpattro, Amvuttra |
| Bayer Healthcare Pharmaceuticals INC. | $134.18 | 2021-2024 | |
| Amarin Pharma, INC. | $134.18 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $105.93 | 2022-2025 | Verquvo |
| Esperion Therapeutics, INC. | $104.11 | 2021-2024 | Nexletol |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cathworks, INC. | $88.73 | 2023 | Ffrangio |
| Scpharmaceuticals INC. | $87.46 | 2023-2025 | |
| Irhythm Technologies, INC. | $86.06 | 2024 | Zio Xt Patch, Zio Monitor |
| Glaxosmithkline, LLC. | $85.97 | 2019-2021 | |
| Kiniksa Pharmaceuticals International, Plc | $65.44 | 2024 | Arcalyst |
| Abiomed | $61.70 | 2023 | Impella |
| Sanofi-Aventis U.S. LLC | $51.62 | 2019 | |
| Medtronic, INC. | $41.53 | 2023 | Onyx Frontier |
| Abbott Laboratories | $39.76 | 2025 | Amplatzer Amulet, Cardiomems |
| Gilead Sciences, INC. | $38.42 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $27.64 | 2022 | |
| Philips North America LLC | $25.93 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $25.83 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $24.69 | 2021 | |
| Bridgebio Pharma, INC. | $24.61 | 2025 | Attruby |
| Regeneron Healthcare Solutions, INC. | $20.79 | 2019 | |
| Genzyme Corporation | $11.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glen Garson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.